Patents by Inventor Noymi V. Yam

Noymi V. Yam has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20120283275
    Abstract: Disclosed are dosage forms and methods comprising benzisoxazole derivatives. More particularly, disclosed are dosage forms, methods, and new uses of benzisoxazole derivatives that substantially reduce or substantially eliminate certain side effects of the benzisoxazole derivatives when dosed to a patient.
    Type: Application
    Filed: May 9, 2012
    Publication date: November 8, 2012
    Inventors: Gayatri Sathyan, Suneel Gupta, Noymi V. Yam, Iran Reyes, Nipun Davar, Atul D. Ayer, Julie Lee, Sonya Seroff
  • Publication number: 20110195981
    Abstract: Disclosed are dosage forms and methods comprising benzisoxazole derivatives. More particularly, disclosed are dosage forms, methods, and new uses of benzisoxazole derivatives that substantially reduce or substantially eliminate certain side effects of the benzisoxazole derivatives when dosed to a patient.
    Type: Application
    Filed: January 24, 2011
    Publication date: August 11, 2011
    Inventors: Gayatri Sathyan, Suneel Gupta, Noymi V. Yam, Iran Reyes, Nipun Davar, Atul D. Ayer, Julie Lee, Sonya Seroff
  • Publication number: 20040033263
    Abstract: Oral delivery vehicles and compositions for providing sustained release of secondary amines including reboxetine with reduced formate poly(alkylene oxide) polymers are provided. Processes for reducing the amount of the formic compounds from the polymers comprising contacting the polymers with an acid having a Pka lower than that of formic acid are also disclosed.
    Type: Application
    Filed: April 28, 2003
    Publication date: February 19, 2004
    Inventors: Sylvia L. Seroff, Noymi V. Yam, Atul D. Ayer, Andrew C. Lam
  • Patent number: 6630165
    Abstract: Dosage forms and methods for providing sustained release of reboxetine are provided. The sustained release dosage forms provide therapeutically effective average steady-state plasma reboxetine concentrations when administered once per day. This once-a-day dosing regimen results in only one peak plasma reboxetine concentration occurrence in each 24 hour period. In addition, the peak plasma reboxetine concentration occurs at a later time following dose administration and exhibits a lesser magnitude than the peak plasma reboxetine concentration that occurs following administration of reboxetine in an immediate-release dosage form.
    Type: Grant
    Filed: February 28, 2002
    Date of Patent: October 7, 2003
    Assignee: Alza Corporation
    Inventors: Sylvia L. Seroff, Noymi V. Yam, Atul D. Ayer, Padmanabh P. Bhatt, Michael A. Desjardin, Andrew C. Lam, David E. Edgren, Phillip R. Nixon
  • Publication number: 20020146453
    Abstract: Dosage forms and methods for providing sustained release of reboxetine are provided. The sustained release dosage forms provide therapeutically effective average steady-state plasma reboxetine concentrations when administered once per day. This once-a-day dosing regimen results in only one peak plasma reboxetine concentration occurrence in each 24 hour period. In addition, the peak plasma reboxetine concentration occurs at a later time following dose administration and exhibits a lesser magnitude than the peak plasma reboxetine concentration that occurs following administration of reboxetine in an immediate-release dosage form.
    Type: Application
    Filed: February 28, 2002
    Publication date: October 10, 2002
    Inventors: Sylvia L. Seroff, Noymi V. Yam, Atul D. Ayer, Padmanabh P. Bhatt, Michael A. Desjardin, Andrew C. Lam, David E. Edgren, Phillip R. Nixon
  • Patent number: 6387403
    Abstract: Dosage forms and methods for providing sustained release of reboxetine are provided. The sustained release dosage forms provide therapeutically effective average steady-state plasma reboxetine concentrations when administered once per day. This once-a-day dosing regimen results in only one peak plasma reboxetine concentration occurrence in each 24 hour period. In addition, the peak plasma reboxetine concentration occurs at a later time following dose administration and exhibits a lesser magnitude than the peak plasma reboxetine concentration that occurs following administration of reboxetine in an immediate-release dosage form.
    Type: Grant
    Filed: September 14, 2000
    Date of Patent: May 14, 2002
    Assignee: ALZA Corporation
    Inventors: Sylvia L. Seroff, Noymi V. Yam, Atul D. Ayer, Padmanabh P. Bhatt, Michael A. Desjardin, Andrew C. Lam, David E. Edgren, Phillip R. Nixon